Prognostic Biomarkers in Patients With Endometrial Cancer
NCT ID: NCT01208467
Last Updated: 2017-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2824 participants
OBSERVATIONAL
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium
NCT02767362
Hysteroscopic Lymphatic Mapping for Endometrial Cancer
NCT00671606
Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer
NCT04046185
Inflammatory Index as a Predictor for Endometrial Cancer: an Observational Study
NCT05657483
Harnessing the Disease Signatures From Endometrium and Menstrual Blood to Identify Avenues for the Treatment of Chronic Conditions Such as Endometriosis and Related Pathologies: This is an Observational Study Aimed at Shedding Light on Women's Health
NCT06990971
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To validate the clinicopathologic associations and prognostic significance of ATR mutation in endometrioid endometrial cancer cases with defective DNA mismatch repair.
OUTLINE: This is a multicenter study.
DNA extracted from previously collected tumor samples is analyzed to validate the clinicopathologic associations and prognostic significance of ATR mutation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Basic science (DNA analysis)
DNA extracted from previously collected tumor samples is analyzed to validate the clinicopathologic associations and prognostic significance of ATR mutation.
Laboratory Biomarker Analysis
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Laboratory Biomarker Analysis
Correlative studies
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women who were registered during the unrestricted enrollment period (through 9/23/07) will automatically qualify
* Women who were registered during the restricted enrollment period (after 9/23/07) will only be considered if needed
* Women who had histologically confirmed endometrioid endometrial adenocarcinoma regardless of stage or grade
* Women who have defective DNA mismatch repair and are microsatellite instability positive (MSI+ and MSI-low)
* Women who consented to allow their specimens and clinical data to be used for future cancer research
* Women who have sufficient high-quality genomic DNA from tumor available for mutation analysis of ATR
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Gynecologic Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Israel Zighelboim
Role: PRINCIPAL_INVESTIGATOR
Gynecologic Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2011-02870
Identifier Type: REGISTRY
Identifier Source: secondary_id
GOG-8017
Identifier Type: -
Identifier Source: secondary_id
CDR0000685834
Identifier Type: -
Identifier Source: secondary_id
GOG-8017
Identifier Type: OTHER
Identifier Source: secondary_id
GOG-8017
Identifier Type: OTHER
Identifier Source: secondary_id
GOG-8017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.